Seattle, WA
Ketamine Therapy clinics in Seattle
Seattle has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Washington permits ketamine infusions by licensed MD/DO and qualified NPs with prescriptive authority under WAC rules. Most Seattle clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Seattle only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Seattle, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Seattle sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Seattle ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Neuroveda Health
- Stem Cell Therapy
- NAD IV Therapy
- Vitamin IV Therapy
- Ozone Therapy
- IV Therapy
Syzygy Psychotherapy Collective
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
- Hormone Replacement Therapy (HRT)
Regulatory context
A note on Washington's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
SB 5263 / Psilocybin Task Force (2023)
Established a state psilocybin task force and authorized a pilot psilocybin services program for veterans and first responders, with UW School of Medicine oversight. -
Local decriminalization
Seattle (2021), Port Townsend, and Olympia have passed resolutions deprioritizing enforcement of entheogenic plants. -
Washington Uniform Controlled Substances Act
Mirrors federal scheduling.
Washington enforces federal scheduling outside the pilot program. The Washington Medical Commission oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Washington PMP requires controlled substance reporting. The UW-affiliated psilocybin pilot operates within federal research compliance.